Alexandria Venture Investments

Solu Therapeutics is a precision medicine company dedicated to developing innovative therapeutics aimed at eliminating cells responsible for driving diseases. Utilizing a unique cytotoxicity-targeting chimera platform, Solu Therapeutics focuses on oncology and also addresses inflammatory and autoimmune diseases. By targeting these disease-driving cells, the company's approach seeks to assist medical professionals in reducing the risks associated with various oncological conditions, ultimately improving patient outcomes and advancing therapeutic options in the healthcare sector.

Autoimmunity BioSolutions is a biotechnology company developing innovative solutions for autoimmune diseases, with a focus on multiple sclerosis. Their core technology involves a next-generation immuno-corrective therapy, tailored to a specific genetic subgroup of autoimmune patients. This therapy aims to restore normal immune function by targeting a specific genetic variant (SNP) driving the autoimmune pathology. The company's platform enables targeted modulation of the immune system, offering potential clients a means to correct immune system dysfunction with precision therapies.

Valora Therapeutics, based in San Diego, California, is a biotechnology company focused on the development of innovative biological drugs. It specializes in engineering chimeric antibodies, which are designed to harness the body's immune system to fight cancer and other diseases. The company operates at the pre-clinical stage, working to unlock new mechanisms of immune signaling and activity, with the aim of providing transformative therapies to the healthcare industry.

Jupiter Bioventures is a venture builder firm dedicated to supporting early-stage therapeutic projects. The company aims to de-risk these initiatives by carefully evaluating opportunities against specific investment criteria. By providing small amounts of seed capital, Jupiter Bioventures enables founders to cultivate their projects and advance their development. Through its focused approach, the firm plays a crucial role in fostering innovation in the therapeutic sector.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

CrossBridge Bio is a biotechnology company focused on developing innovative antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes proprietary linker technology and enzymatic conjugation methods to create stable and targeted ADC therapeutics. This approach aims to improve the efficacy and safety profiles of cancer therapies, offering potential advancements in the treatment landscape. By leveraging its unique dual linker payload technology, CrossBridge Bio seeks to revolutionize how cancer is treated, providing new options for patients and healthcare providers.

Archon Bio is a biotechnology company that specializes in engineering proteins to enhance therapeutic outcomes. It focuses on creating self-assembling protein antibody nanomaterials, aiming to improve immune modulation and super agonism of the TNF receptor superfamily. By increasing the size and valency of off-the-shelf antibodies, Archon seeks to induce stronger responses, thereby advancing regenerative medicine and cancer treatment.

Leal Therapeutics is a Massachusetts-based company focused on developing innovative therapeutics for patients with significant central nervous system conditions. The company addresses urgent and unmet medical needs by providing precision medicines tailored to improve patient outcomes. Through its dedication to advancing therapeutic services, Leal Therapeutics aims to enhance the quality of care for individuals affected by challenging neurological disorders.

March Biosciences is a clinical-stage biotechnology company specializing in cell therapies for hematological cancers. Its primary focus is on developing CAR-T cell therapies, with a lead asset, MB-105, targeting CD5 in refractory T-cell lymphoma and leukemia, currently in Phase 1 trials. The company's approach involves biologically informed target selection, simplified CAR-T engineering, and a streamlined manufacturing process that prioritizes cell functionality and consistency.

Passkey Therapeutics is pioneering a new class of medicines, Synergistic Multifunctional Therapeutics (SMThs). It is designed to address complex diseases by targeting rare combinations of proteins that work together.

Terray Therapeutics is a biotechnology company based in Pasadena, California, founded in 2018. The company specializes in developing innovative treatments for complex human diseases by integrating experimentation and computation to enhance small molecule drug discovery. Terray's unique platform employs ultra-dense microarray technology alongside artificial intelligence and synthetic chemistry to generate extensive and precise chemical datasets. This allows for a rapid design-make-test-analyze cycle, facilitating efficient exploration of chemical space and mapping biochemical interactions between small molecules and disease causes. By utilizing automation and machine learning, Terray addresses significant therapeutic challenges, ultimately guiding the next cycles of drug design and experimentation.

Judo Bio is a biotechnology company focused on developing precision therapeutics that target specific cell populations to treat genetic diseases. Utilizing an innovative receptor targeting approach, Judo Bio is building a pipeline of therapies designed to benefit patients suffering from both common and rare conditions. Currently, the company is operating in stealth mode, indicating a focus on research and development without public visibility.

858 Therapeutics is a biotechnology company dedicated to the discovery of small molecule therapeutics aimed at treating cancers and other diseases, particularly those resistant to existing therapies. The company employs innovative strategies in areas such as synthetic lethality, innate immunity, and RNA modulation to develop its therapeutic candidates. Its lead program focuses on a PARG inhibitor, which is currently in early clinical development. By leveraging its platform to investigate the role of RNA modifying proteins in disease biology, 858 Therapeutics is generating a pipeline of targeted small molecules that address critical unmet medical needs in oncology and immunology.

Radiant Biotherapeutics is an innovative company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by producing multi-functional biologics capable of addressing challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging enhanced binding power and multi-specificity, Radiant Biotherapeutics seeks to create potent therapeutics that have the potential to significantly improve treatment outcomes for patients. The company is committed to delivering transformative therapies through its cutting-edge approach to antibody technology.

AIRNA is a biotechnology company specializing in the development of RNA editing therapies. Its platform enables the creation of therapeutics designed to treat both rare and common diseases, with the goal of improving patients' health.

Bright Peak Therapeutics is a biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases. The company specializes in cytokine therapeutics that enable tissue and cell-specific targeting of cytokine payloads. This approach aims to enhance the efficacy of treatments, ultimately improving patient outcomes and quality of life. By leveraging innovative immuno-cytokines, Bright Peak seeks to provide more effective therapeutic options for complex medical conditions.

OverT Bio is a biotechnology company focused on developing cell therapies for cancer treatment. The company specializes in identifying and creating novel genetic modifications that empower immune cells to navigate and overcome the barriers posed by tumors. By enhancing the effectiveness and durability of immunotherapies, OverT Bio aims to advance the healthcare field's ability to identify and ultimately cure cancer.

Delphia Therapeutics, headquartered in Boston, USA, is a biotechnology company focused on developing innovative cancer treatments. It operates a laboratory where researchers study cancer-driving pathways to create targeted therapies. The company's approach involves selectively over-activating certain cancer-linked cell signaling pathways, making tumor cells unsustainable and enabling more effective cancer treatment for patients.

Enlaza Therapeutics is a biotechnology research company founded in 2020 and based in La Jolla, California. The company focuses on developing novel protein therapeutics aimed at providing more effective and safer treatment options for patients. Utilizing advanced synthetic biology technology, Enlaza's platform enables site-specific covalent coupling driven by drug binding. This innovative approach allows for the creation of first-in-class covalent biologics, which are designed to offer enhanced efficacy and improved safety profiles compared to existing treatments.

Clasp Therapeutics is focused on advancing cancer treatment through its innovative immunotherapeutics platform. The company develops precision medicines designed to enhance the immune system's ability to identify and eliminate challenging tumors that possess common driver mutations, irrespective of the tumor type. By enabling the targeting of cancer-specific markers, Clasp Therapeutics aims to allow for precise and selective destruction of tumor cells, thereby improving therapeutic outcomes in the field of immuno-oncology.

Tr1x is a biotechnology company focused on developing cellular therapies for the treatment of autoimmune disorders. The company leverages its proprietary platform to create advanced cell therapy products aimed at recalibrating the immune system and restoring homeostasis. By exploring genetic engineering and T-cell biology, Tr1x seeks to develop scalable and effective cellular cures that target inflammation and autoimmunity. Its mission is to provide innovative solutions for autoimmune and inflammatory diseases, ultimately transforming the lives of patients affected by these conditions.

Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies that target RNA processing to address various diseases. Established in 2018 and based in Cambridge, Massachusetts, the company employs its proprietary biology platform to identify and prioritize therapeutic targets within RNA processing. Through its REMseq platform, Remix Therapeutics validates potential drug targets and optimizes chemical compounds for therapeutic use. The company's approach aims to reprogram RNA processing to control gene expression, thereby correcting, enhancing, or eliminating problematic gene messages. This enables healthcare providers to tackle the underlying causes of diseases, offering novel solutions to previously undruggable conditions.

Tome Biosciences is a biotechnology company specializing in programmable gene insertion technology. Utilizing CRISPR, the company develops methods to insert genetic sequences of any size at various locations within any genome. This innovative approach aims to enhance the ability to detect and eliminate deoxyribonucleic acid from similar bacteriophages during infections. By advancing cell and genome engineering, Tome Biosciences seeks to provide effective therapeutic solutions for patients, paving the way for significant advancements in genetic medicine.

Ability Biologics is a biotechnology company focused on developing innovative immune-modulating biotherapeutics to meet the pressing medical needs of patients suffering from cancer and autoimmune diseases. The company leverages an advanced platform that employs continuously learning artificial intelligence and a comprehensive database of antigen-antibody interactions. This technology enables the creation of potent and selective antibody therapeutics, aimed at addressing significant gaps in treatment options for these challenging health conditions. By prioritizing tailored solutions, Ability Biologics seeks to enhance patient outcomes and contribute to advancements in the field of immunotherapy.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on improving mental health treatment through personalized medicine. By utilizing an AI-enabled biomarker platform, Alto integrates detailed patient data regarding brain activity and behavior to develop effective therapeutics for specific populations. The company aims to transform the traditional trial-and-error approach in psychiatry by matching the appropriate treatment to individual patients, thereby enhancing the effectiveness of interventions. Alto's clinical-stage assets include various products targeting conditions such as depressive disorders and schizophrenia, identified through independent brain-based biomarkers. Through its innovative approach, Alto Neuroscience seeks to redefine psychiatric care at a critical time for mental health.

Triveni Bio is a biotechnology company specializing in the development of novel antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven precision medicine approach to identify patients most likely to respond to its treatments, aiming to accelerate drug development and improve the effectiveness and safety of therapies.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company is dedicated to creating life-changing medicines with disease-specific applications that enhance patient outcomes. By leveraging improved pharmacokinetics and pharmacodynamics, DEKA Biosciences aims to deliver dual and complementary cytokines directly to affected tissues or cells. This targeted approach seeks to provide patients with curative treatment options for a range of conditions, including cancer, autoimmune disorders, and infectious diseases.

Arialys Therapeutics is a pre-clinical stage biotechnology company that specializes in neuroscience, particularly in the development of precision medicines aimed at blocking pathogenic autoantibodies in the brain. The company investigates the role of the immune system in central nervous system (CNS) health and disease, focusing on the characterization and prevalence of pathogenic auto-antibody activity. Arialys Therapeutics aims to provide advanced therapies for various CNS disorders, including neuropsychiatric conditions linked to autoimmune diseases, thereby contributing to the healthcare industry's efforts to address complex neurological challenges.

Georgiamune is an immunotherapy company dedicated to advancing oncology treatments. The firm specializes in next-generation immunotherapeutic and homeostatic therapies aimed at addressing cancer and autoimmune diseases. By focusing on innovative approaches, Georgiamune seeks to enhance patient recovery from cancer, contributing to significant breakthroughs in the field of immunotherapy.

Solu Therapeutics is a precision medicine company dedicated to developing innovative therapeutics aimed at eliminating cells responsible for driving diseases. Utilizing a unique cytotoxicity-targeting chimera platform, Solu Therapeutics focuses on oncology and also addresses inflammatory and autoimmune diseases. By targeting these disease-driving cells, the company's approach seeks to assist medical professionals in reducing the risks associated with various oncological conditions, ultimately improving patient outcomes and advancing therapeutic options in the healthcare sector.

Bitterroot Bio is a biotechnology company focused on developing innovative immunotherapy-based treatments for cardiovascular disease. By harnessing the immune system's natural capabilities to combat illness, the company conducts research to understand the significant roles of immune cells and immune modulators in the onset and advancement of cardiovascular conditions. Through its commitment to advancing medical treatments, Bitterroot Bio aims to provide effective therapies that can transform cardiovascular disease management and improve patient outcomes.

Myeloid Therapeutics is an immunology company dedicated to harnessing myeloid cells for the treatment of cancer and other diseases. The company employs its ATAK platform technology, which focuses on reprogramming innate immune cells to enhance their ability to target and eliminate cancerous cells. This platform is designed to be versatile and scalable, allowing for the development of various treatment modalities across multiple disease areas. Currently, Myeloid Therapeutics is advancing a cell therapy program aimed at T cell lymphoma, as well as a primed monocyte approach for treating glioblastoma. Through its innovative technology, the company seeks to overcome the limitations of existing cell therapies and improve patient outcomes.

Ten63 Therapeutics is a biotechnology company focused on developing innovative therapeutics for challenging diseases, particularly those involving targets previously considered undruggable. Founded in 2017 and based in Chapel Hill, North Carolina, the company utilizes its proprietary platform, COPPER, which integrates advanced artificial intelligence and state-of-the-art physical models to explore vast chemical spaces. By employing low-residual, machine learning-based computational chemistry alongside superlinear search algorithms, Ten63 Therapeutics aims to identify and optimize drug candidates effectively. Their approach includes proprietary scaffold redesign and hopping technology, enabling the screening of trillions of molecules to predict resistance and redesign antibodies. This combination of techniques positions Ten63 Therapeutics at the forefront of developing durable treatments for some of the most lethal diseases.

Radiant Biotherapeutics is an innovative company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by producing multi-functional biologics capable of addressing challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging enhanced binding power and multi-specificity, Radiant Biotherapeutics seeks to create potent therapeutics that have the potential to significantly improve treatment outcomes for patients. The company is committed to delivering transformative therapies through its cutting-edge approach to antibody technology.

TORL BioTherapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative antibody-based medicines aimed at improving outcomes for cancer patients. The company specializes in creating antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs) to address oncologic diseases that exhibit significant unmet medical needs. TORL BioTherapeutics employs a strategic approach that includes target identification and early discovery work, allowing them to license promising drug programs and develop proprietary therapies with optimized characteristics. Through this pipeline, TORL BioTherapeutics is positioned to advance novel treatments that could significantly enhance patient care in oncology.

Function Oncology is a precision medicine company focused on developing advanced cancer therapies through a personalized functional genomics platform powered by CRISPR technology. This innovative platform allows for the identification of therapeutic opportunities tailored to individual patients, enhancing the understanding of cancer at a patient-specific level. By leveraging cutting-edge genomic tools, Function Oncology aims to transform targeted cancer treatment and create the next generation of therapies designed to meet the unique needs of each patient.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing gene therapies through its innovative Anellovector platform. This platform leverages the biology of the human commensal virome to create redosable and targetable DNA therapies that address several limitations of existing gene therapies, such as restricted access to various tissues, risks associated with genomic integration, and issues with tolerability. Founded in 2017, the company aims to expand the applications of gene therapy beyond traditional gene replacement, targeting a wide range of conditions including genetic disorders, ophthalmology, oncology, and metabolic diseases. By doing so, Ring Therapeutics seeks to provide healthcare solutions that allow for a broader array of therapeutic modalities and improved patient outcomes.

Paratus Sciences is a biotechnology company focused on enhancing human health and health security through the study of bat biology. By exploring the unique aspects of the bat genome, the company aims to identify and develop therapeutics for a variety of diseases. Paratus Sciences seeks to unlock the secrets of bat biology to facilitate innovative treatments, ultimately helping patients combat the health challenges they encounter.

Garuda Therapeutics is a biotech company focused on developing off-the-shelf hematopoietic stem cell therapies aimed at treating life-threatening diseases, particularly those affecting blood, bone marrow, immunity, and metabolism. The company is dedicated to eliminating the reliance on donor or patient cells for blood stem cell transplants by leveraging its innovative platform technology to generate self-renewing blood stem cells. This approach is designed to ensure rapid and broad access to consistent, durable, HLA-compatible, and transgene-free blood stem cell therapies for patients. Garuda Therapeutics employs advanced methodologies, including the use of zebrafish, mice, and human-induced pluripotent stem cells, to clone and analyze novel genes and mechanisms critical for blood formation, ultimately developing mechanism-based therapies that address unmet medical needs.

Dantari is a biotechnology company focused on developing innovative medicines for the treatment of serious diseases, including cancer and conditions affecting the central nervous system. The company utilizes a pharmaceutical platform that emphasizes the research and development of both small and large molecule therapeutics capable of crossing the blood-brain barrier. Dantari's advanced technology features a higher drug-to-antibody ratio than traditional antibody-drug conjugates (ADCs), allowing for tunable release of therapeutic payloads and the delivery of larger payloads. This approach aims to enhance efficacy and expand the therapeutic potential of its treatments, ultimately improving patient health and providing meaningful medical advancements.

Cajal Neuroscience is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases. By integrating human genetics, functional genomics, and advanced microscopy, the company aims to identify novel therapeutic targets. Cajal utilizes a range of cutting-edge technologies, including high-throughput functional genomics and multi-omics approaches, to screen for targets that significantly influence the progression of neurodegenerative diseases. This comprehensive methodology supports the development of precision medicine, ultimately aiding healthcare professionals in treating patients affected by these conditions.

Rezo Therapeutics is a biotechnology company that focuses on developing precision therapeutics by mapping disease networks. Utilizing its proprietary Sequence to Systems to Drugs (SSD) platform, Rezo integrates various technologies, including proteomics, genetics, structural biology, chemistry, and bioinformatics, to create comprehensive molecular maps of diseases. This innovative approach enhances the identification of novel targets and therapies, particularly in oncology, where Rezo initially concentrates its efforts. The company aims to expand its therapeutic focus through collaborations and partnerships, positioning itself at the forefront of advancing treatment options across multiple disease areas.

Haystack Oncology is an oncology company that specializes in liquid biopsy diagnostic technology aimed at improving cancer treatment strategies and patient outcomes. By utilizing advanced circulating tumor DNA detection methods, the company enhances the diagnosis of minimal residual disease, allowing for more informed therapy decision-making. Their technology focuses on identifying tumor-specific markers through blood samples, which facilitates the early detection of recurrent disease and offers increased sensitivity in monitoring residual disease post-treatment. This innovation enables healthcare teams to access cutting-edge liquid biopsy tools, thereby transforming the management of cancer and significantly improving patient care.

Matchpoint Therapeutics is a biotechnology company focused on developing precision covalent medicines aimed at transforming the treatment of immune diseases and other serious conditions. Utilizing its proprietary Advanced Covalent Exploration (ACE) platform, the company combines advanced chemoproteomics, machine learning, and the evolution of covalent chemistry libraries to enhance drug discovery. This innovative approach allows for a deeper exploration of the proteome, enabling the identification and targeting of new binding sites on disease-causing proteins. Matchpoint is building an emerging pipeline of novel covalent medicines, with an initial emphasis on immunology.

Tavros Therapeutics is a biotechnology company founded in 2019 and based in Durham, North Carolina. The company focuses on discovering and developing therapies for cancer, aiming to improve oncological treatment outcomes. Tavros Therapeutics is dedicated to identifying vulnerabilities within tumors, which allows for the targeted application of specific drugs in conjunction with optimal combinations. This approach is intended to enhance the effectiveness of cancer treatments and increase the potential for patient cures.

Capstan Therapeutics is a biotechnology company focused on enhancing the therapeutic potential of in vivo RNA-based therapies. It develops proprietary targeted delivery systems, including targeted lipid nanoparticles, to improve the efficacy and control of dosage in engineered cell therapies. This innovative platform aims to address a variety of diseases, particularly in the fields of oncology, fibrosis, and inflammation, where there are significant unmet clinical needs. By advancing precision in vivo cell engineering, Capstan Therapeutics seeks to create transformative therapeutics that can offer new solutions for patients facing these challenging conditions.

Novome Biotechnologies, Inc. is a biotechnology company that focuses on engineering bacteria from the human gut to develop innovative treatments for chronic diseases. Its proprietary platform, which allows for the controlled colonization of the gut with genetically engineered microbial medicines (GEMMs), is designed to provide sustained therapeutic effects. Novome's lead preclinical program targets hyperoxaluria by developing a therapeutic strain of bacteria that degrades oxalate, thereby preventing kidney stone formation. The company aims to leverage its synthetic biology tools to expand its applications into additional health conditions, enhancing its ability to deliver precise therapeutic activities through engineered gut microbiota. Founded in 2015, Novome is headquartered in South San Francisco, California.

Senda Biosciences, founded in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company specializes in studying the molecular relationships between bacterial, botanical, and human cells to understand how these interactions influence health and disease. By gaining insights into these interspecies connections, Senda Biosciences aims to create novel categories of medicines and delivery methods, providing medical professionals with new tools to combat various illnesses.

Cartography Biosciences is a biotechnology company focused on developing cancer therapies through precision medicine. The company has created a platform-based cell therapy that utilizes single-cell analysis to identify innovative CAR-T targets. This approach allows for the design of cancer immunotherapies tailored to the safest and most effective targets. By combining molecular biology and computational methods, Cartography enables clients to advance their studies in the development of these targeted treatments, aiming to improve outcomes for cancer patients.

DEM BioPharma is an immuno-oncology company focused on developing innovative therapies aimed at eradicating cancer by targeting the innate immune system. The company has created a platform that specializes in the next generation of macrophage immunotherapies, which work by activating macrophages and immune phagocytes to effectively eliminate tumors. By researching and harnessing these immune responses, DEM BioPharma aims to provide healthcare researchers with advanced treatments that specifically target signals on both cancer cells and macrophages, offering new hope in the fight against cancer.

Dren Bio is a biotechnology company that specializes in protein engineering technologies designed to target and deplete pathogenic cells, protein aggregates, and other disease-causing agents. With a focus on hematologic neoplasms, solid cancers, autoimmune disorders, and diseases related to protein aggregation, the company aims to provide innovative solutions for healthcare professionals in their efforts to combat various serious diseases. Operating under a holding company model, Dren Bio develops multiple projects as standalone assets, seeking to create value through its diverse portfolio of biotechnology initiatives.

Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies that target RNA processing to address various diseases. Established in 2018 and based in Cambridge, Massachusetts, the company employs its proprietary biology platform to identify and prioritize therapeutic targets within RNA processing. Through its REMseq platform, Remix Therapeutics validates potential drug targets and optimizes chemical compounds for therapeutic use. The company's approach aims to reprogram RNA processing to control gene expression, thereby correcting, enhancing, or eliminating problematic gene messages. This enables healthcare providers to tackle the underlying causes of diseases, offering novel solutions to previously undruggable conditions.

Pheast Therapeutics is a cancer immunotherapy company founded in 2020 and based in Palo Alto, California. The company specializes in developing innovative checkpoint therapies aimed at activating the innate immune system to combat cancer. Its primary focus is on creating immunotherapies that target macrophage checkpoints, which are crucial for enabling macrophages to effectively eliminate tumors in ovarian and breast cancers. By blocking these immune checkpoints, Pheast Therapeutics aims to enhance the likelihood of patient survival and advance treatment options within the healthcare sector.

Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer. Affini-T uses a validated platform to select high-affinity T cell receptors specific to oncogenic mutations to pioneer cutting-edge solid tumor therapies. Affini-T leverages gene editing and synthetic biology to engineer novel T-cell therapies designed to eradicate tumors.

Eclipse Bioinnovations, founded in 2017 based on technology from the University of California, San Diego, specializes in RNA genomics. The company aims to advance RNA medicines and scientific discovery through its innovative platform technologies. Eclipse has developed eCLIP, a unique and efficient method for identifying RNA binding protein partners and gene maps. Its suite of RNA genomics technologies includes eCLIP-RBP for mapping RNA binding proteins, miR-eCLIP for studying the miR-interactome, m6A-eCLIP for RNA modifications, End-Seq for 5' and 3' mapping, and FLI-Seq for facilitating CRISPR library preparation. Eclipse offers these products as both services and kits, tailored for biopharma companies and academic researchers, enabling them to enhance their research and develop new therapies for various human diseases.

Creyon Bio is a pre-clinical stage company focused on advancing drug development through a data-driven methodology. It specializes in engineering RNA-based medicines and their components by creating proprietary datasets that inform advanced machine learning models. This innovative approach enables the rapid identification of design rules and engineering principles necessary for the development of safe and effective oligonucleotide-based medicines. By leveraging these insights, Creyon Bio aims to improve the efficiency of the drug development process, ultimately contributing to cost savings in the healthcare sector while catering to diverse patient populations.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Terray Therapeutics is a biotechnology company based in Pasadena, California, founded in 2018. The company specializes in developing innovative treatments for complex human diseases by integrating experimentation and computation to enhance small molecule drug discovery. Terray's unique platform employs ultra-dense microarray technology alongside artificial intelligence and synthetic chemistry to generate extensive and precise chemical datasets. This allows for a rapid design-make-test-analyze cycle, facilitating efficient exploration of chemical space and mapping biochemical interactions between small molecules and disease causes. By utilizing automation and machine learning, Terray addresses significant therapeutic challenges, ultimately guiding the next cycles of drug design and experimentation.

Ambys Medicines, Inc. is a biotechnology company based in Redwood City, California, founded in 2016. The company is dedicated to discovering and developing transformative therapies for severe liver diseases. Ambys focuses on creating innovative gene, drug, and cell therapies aimed at restoring liver function, halting the progression of liver disease, and addressing the complications associated with liver failure. By leveraging regenerative and restorative medical approaches, Ambys Medicines seeks to improve the lives of individuals affected by chronic liver conditions, providing potential relief through advanced therapeutic options.

NextVivo is a biotechnology company focused on advancing drug development through its innovative immune organoid technology platform. This platform generates human cell and antibody candidate therapies by harnessing the body's immune system. NextVivo's organoids are miniature 3D cell cultures designed to replicate the composition, structure, and function of human tissues, allowing for a realistic modeling of the humoral and cellular immune responses outside the body. This technology enables the testing of pre-clinical candidates on ex vivo human tissue models, facilitating the identification of the most effective therapies for clinical development. The company's mission is to accelerate the creation of safer and more effective treatments by utilizing immune-competent, human-derived models.

Fountain Therapeutics, Inc. is a biotechnology company focused on developing treatments for age-related diseases. Founded in 2018 and based in San Francisco, California, the company aims to create a future where individuals live healthier for longer. It employs a transformative cellular model that mimics the complex characteristics of aging within a laboratory setting. By integrating this model with advanced artificial intelligence and computer vision, Fountain Therapeutics seeks to establish an innovative platform for identifying novel therapeutic targets. This approach is designed to facilitate the development of effective treatments for diseases associated with aging, ultimately aiming to reverse cellular aging and improve health outcomes.

GeneCentric Therapeutics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company currently has two unique platform technologies including The Lung Subtype Platform (LSP) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The first application of LSP was licensed to and independently developed by Laboratory Corporation of America Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. Its second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies. GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. The company was incorporated in 2011 and is based in Durham, North Carolina.

Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.

Nitrase Therapeutics is a biopharmaceutical platform company focused on developing therapies targeting a newly identified class of enzymes known as Nitrases. Initially concentrating on Parkinson’s disease, the company aims to create drugs that may slow or halt the progression of this and other related neurodegenerative conditions. By leveraging its expertise in nitration, Nitrase Therapeutics seeks to explore the therapeutic potential of biochemical modifications of proteins, particularly through the identification of nitro-substrates and their involvement in various diseases. This approach positions the company to potentially expand its platform to address a broader range of medical conditions in the future.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company is dedicated to creating life-changing medicines with disease-specific applications that enhance patient outcomes. By leveraging improved pharmacokinetics and pharmacodynamics, DEKA Biosciences aims to deliver dual and complementary cytokines directly to affected tissues or cells. This targeted approach seeks to provide patients with curative treatment options for a range of conditions, including cancer, autoimmune disorders, and infectious diseases.

Mozart Therapeutics is a biotechnology startup dedicated to developing disease-modifying therapies for autoimmune and inflammatory diseases. The company focuses on a novel regulatory CD8 T cell network to create innovative CD8 Treg modulators aimed at treating a range of autoimmune conditions. By targeting a specific subset of T-lymphocytes, Mozart aims to restore long-term immune balance and prevent the progression of damage caused by autoreactive immune responses. Its pipeline includes first-in-class CD8 Treg modulators designed to delay the onset of autoimmune diseases and improve patient outcomes through advanced treatment options.

IpiNovyx Bio is a biopharmaceutical company focused on creating a novel platform of immunoproteasome-modulating therapeutics aimed at improving the treatment of autoimmune and inflammatory diseases. The company's innovative approach involves developing inhibitors that selectively target the immunoproteasome, which plays a critical role in regulating specific immune cell types. By modulating these immune responses, IpiNovyx Bio seeks to enable patients to recover more effectively from their conditions and enhance their overall health.

Acrigen Biosciences focuses on enhancing the safety and efficacy of gene editing technologies, particularly those based on the CRISPR-Cas system. Founded in 2019 and headquartered in Berkeley, California, the company develops innovative solutions that aim to produce effective in vivo drug therapies to combat various diseases. Acrigen's proprietary technologies include Acro proteins that regulate the CRISPR-Cas gene editing process and an advanced bioinformatics discovery software platform that identifies suitable CRISPR systems for human therapeutic applications. Through these advancements, Acrigen Biosciences seeks to improve the precision, efficacy, and safety of genetic therapies, ultimately contributing to the potential prevention and cure of debilitating diseases.

Kytopen, established in 2017 and based in Cambridge, Massachusetts, specializes in the development of a cell therapy platform. This platform facilitates the non-viral delivery of molecules into challenging-to-transfect immune cells, making the process easier, faster, and more cost-effective. The company's proprietary Flowfect™ technology combines microfluidics and automation, enabling researchers to explore new biological discoveries and develop more affordable cell and gene therapies.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, the company utilizes the repeatome—a previously overlooked segment of genetic material—to create novel treatment options. By identifying multiple drug targets and advancing several discovery programs, ROME Therapeutics aims to tap into this unexplored area of biology. The organization has assembled a team of experts in oncology, immunology, virology, and machine learning to lead its research and development efforts, which are designed to provide healthcare professionals with effective new treatments for patients suffering from these conditions.

Lycia Therapeutics is a biotechnology firm focused on discovering and developing first-in-class therapies. The company utilizes its innovative lysosomal targeting chimeras (LYTACs) platform to create therapeutics that target and degrade extracellular and membrane-bound proteins associated with challenging diseases, including cancer and autoimmune disorders. By addressing these difficult-to-treat conditions, Lycia Therapeutics aims to provide medical practitioners with effective treatment options to improve patient outcomes.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for severe hematologic disorders. Founded in 2017, the company specializes in human genetics-based therapeutics that aim to improve red blood cell production in patients suffering from various hematologic diseases. Disc Medicine's pipeline includes therapeutic candidates targeting critical pathways involved in red blood cell biology, such as heme biosynthesis and iron homeostasis. Notable programs include bitopertin, which is being developed for conditions like erythropoietic porphyrias and Diamond-Blackfan anemia. Through its research and development efforts, Disc Medicine seeks to transform the lives of patients affected by these challenging disorders.

Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.

eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company based in San Diego, California. Established in 2012, the company specializes in developing selective translation regulators for cancer and other serious diseases. Its innovative approach involves small molecule drugs known as selective translation regulator inhibitors (STRIs), which target the eIF4F complex and its associated kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). This complex plays a crucial role in the translation of specific messenger RNA into proteins linked to cancer progression. eFFECTOR's lead product candidate, tomivosertib, is currently being evaluated in a Phase 2b trial in combination with pembrolizumab for non-small cell lung cancer. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation trials with plans for further expansion. The company also collaborates with Pfizer to develop inhibitors targeting eIF4E. Through these efforts, eFFECTOR aims to address the challenges of tumor growth, survival, and immune evasion in cancer treatment.

Thryv Therapeutics is a precision medicine company focused on developing innovative therapies for Long QT Syndrome and various arrhythmias. The company employs a precision medicine approach to address both genetic and drug-induced long QT syndrome, atrial fibrillation, and treatment-resistant cancers. Thryv Therapeutics is dedicated to creating potent and selective inhibitors of Serum Glucocorticoid Inducible Kinase, aiming to reduce the risk of sudden cardiac death and enhance the quality of life for affected patients. Through its targeted therapeutic development, the company seeks to provide effective solutions for serious cardiovascular and oncological conditions.

Wugen is focused on developing off-the-shelf cellular therapies for cancer, particularly utilizing natural killer (NK) cells and CAR-T cell therapies. The company enhances NK cells obtained from healthy donors to improve their ability to target and eliminate cancer cells. Wugen's innovative approach includes a proprietary platform that leverages advanced genomic engineering to create next-generation memory NK cell therapies. These therapies specifically aim to address various types of malignancies, including solid tumors, acute myeloid leukemia, and T-cell malignancies, thereby providing new treatment options for patients facing life-threatening cancers.

Axonis Therapeutics is a biotechnology company focused on developing therapies for neurological disorders by targeting KCC2, a key mediator of inhibition in the brain. The company utilizes a proprietary discovery engine centered on the neuron-specific K-Cl cotransporter (KCC2) to address various conditions, including epilepsy and pain, as well as other central nervous system pathologies. By harnessing breakthrough research from institutions such as Boston Children’s Hospital, Harvard, and Laval University, Axonis aims to enhance the lives of individuals affected by these disorders through improved modulation of neuronal inhibition.

Cyrus Biotechnology, Inc. is a Seattle-based company that specializes in developing advanced software for protein structure prediction and design. Founded in 2014, it offers several key products, including Rosetta, a tool designed to create biologically active proteins for various medical applications such as treating brain cancer and addressing Celiac Disease. The company also provides Cyrus Bench, an enterprise version of Rosetta that includes a comprehensive suite of bio-molecular computation tools. Additionally, Cyrus Biotechnology offers specialized services like Cyrus CryoEM, which focuses on structure refinement and model building for complex biomolecular structures. Its innovative software solutions cater to pharmaceutical companies, biotech firms, and startups engaged in discovering therapeutics and developing novel consumer products.

ImmuneID is a precision immunology company that has developed a proprietary platform aimed at identifying and therapeutically targeting antibody interactions involved in immune diseases. The platform utilizes advanced methodologies, including massively parallel, multiplexed, and unbiased systems, to facilitate the development of therapeutics for various conditions such as autoimmunity, severe allergies, oncology, and infectious diseases. By enabling researchers to observe and analyze human immune responses across different stages of disease progression, ImmuneID seeks to enhance the understanding of immune mechanisms and improve treatment strategies.

Neurona Therapeutics Inc. is a biotechnology company based in South San Francisco, California, that specializes in developing cell-based therapies for neurological disorders. Founded by neuroscientists and stem cell pioneers at The University of California, San Francisco, the company focuses on creating therapeutic compositions of specific types of neurons for targeted delivery into the injured nervous system. Drawing on nearly two decades of research, Neurona seeks to harness particular subpopulations of neurons capable of integrating and repairing dysregulated neural circuits. With a dedicated team of scientists and advisors, the company aims to accelerate the development of breakthrough treatments for patients suffering from significant unmet medical needs in the realm of chronic neurological diseases.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying pathologies of thrombosis and type one diabetes. The company focuses on innovative treatment paradigms informed by a deep understanding of the molecular mechanisms involved in these diseases. By targeting conditions such as heparin-induced thrombocytopenia and thrombosis, Veralox Therapeutics aims to enhance patient outcomes and facilitate complete recovery from diabetes. Through its research and development efforts, the company seeks to provide effective and transformative therapies for individuals affected by these serious health conditions.

Mnemo Therapeutics is a biotechnology firm focused on developing immune-based therapies, particularly cell therapies, aimed at treating solid tumors and blood cancers. The company utilizes its EnfiniT platform, a drug discovery engine that harnesses a unique class of antigens and various technologies to target tumorous epitopes prevalent in multiple cancer types. By leveraging epigenetic variation and CAR-T precision genetic engineering, Mnemo Therapeutics strives to create accessible allogeneic treatments that offer effective solutions for patients facing these challenging diseases.

Senda Biosciences, founded in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company specializes in studying the molecular relationships between bacterial, botanical, and human cells to understand how these interactions influence health and disease. By gaining insights into these interspecies connections, Senda Biosciences aims to create novel categories of medicines and delivery methods, providing medical professionals with new tools to combat various illnesses.

Bright Peak Therapeutics is a biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases. The company specializes in cytokine therapeutics that enable tissue and cell-specific targeting of cytokine payloads. This approach aims to enhance the efficacy of treatments, ultimately improving patient outcomes and quality of life. By leveraging innovative immuno-cytokines, Bright Peak seeks to provide more effective therapeutic options for complex medical conditions.

Kojin Therapeutics, founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, focuses on advancing a drug discovery platform that links complex cell states to established biochemical processes, specifically ferroptosis, which involves iron-dependent cell death. This innovative approach enables the development of targeted therapies for a wide range of challenging diseases that are often difficult to treat. The company's biology platform aims to identify disease-specific targets, ensuring that patients receive effective treatments tailored to their specific conditions. Kojin Therapeutics is supported by a diverse group of investors, including Polaris Partners, Newpath Partners, and AbbVie, among others.

miRecule, Inc. is a biotechnology company based in Gaithersburg, Maryland, established in 2016. The company specializes in developing a microRNA-based drug discovery platform, DREAmiR, aimed at addressing challenges in cancer therapy and muscular dystrophy. This innovative platform leverages genomic and outcome data from thousands of patients to identify genetic abnormalities associated with diseases. miRecule formulates RNA therapeutics that can directly target and correct these genetic issues. The platform integrates genomic sequencing, expression, and prognostic data from numerous cancer patients with high throughput screening of microRNA candidates for replacement therapy. miRecule is focused on creating highly tailored therapeutics, with lead programs targeting Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy, ultimately striving to improve the quality of life for patients suffering from debilitating conditions.

Soteria Biotherapeutics, Inc., founded in 2018 and based in San Francisco, California, focuses on developing innovative immunotherapies for cancer treatment. The company is creating a new generation of conditionally active bispecific T-cell engaging antibodies specifically aimed at treating solid tumors. Utilizing its advanced T-LITE™ platform, Soteria enables small molecule-dependent activation of these bispecific antibody therapies, which facilitates safer and more effective treatment options. This approach allows for pulsatile activity, resulting in reduced side effects and the potential for higher dosing, thereby improving the overall therapeutic experience for patients.

Ventus Therapeutics is a biopharmaceutical company focused on discovering and developing novel small molecule medicines aimed at treating autoimmune diseases, inflammatory diseases, and cancer by targeting the innate immune system. The company employs a structural immunology platform that provides deep insights into the mechanisms and molecular structures involved in immune responses. This platform integrates proprietary protein engineering capabilities with advanced rational and structure-based drug design tools, allowing for precise targeting of the innate immune system. Ventus is actively building a pipeline of drug programs that address critical targets within this system, particularly proteins involved in inflammasome and nucleic acid-sensing signaling pathways, thereby enabling the treatment of both acute and chronic inflammatory and immune-related conditions.

Alloy Therapeutics is a biotechnology company based in Waltham, Massachusetts, founded in 2017. The company focuses on democratizing access to essential drug discovery platforms and services, primarily through its Alloy-Gx platform. This innovative platform features a royalty-free suite of immunocompetent transgenic mice that facilitate in vivo human antibody discovery. Alloy Therapeutics has developed humanized transgenic antibody discovery technology, which offers broad, non-exclusive access to drug discovery tools, allowing scientists to engage in their antibody projects more efficiently and effectively. The company's mission is to enhance the drug discovery process by providing accessible and advanced resources for researchers in the field.

Vera Therapeutics, a biotechnology company based in South San Francisco, California, specializes in developing innovative biologic therapeutics aimed at treating serious immunological diseases and genetic disorders. Founded in 2016 and renamed in March 2020, the company's research focuses on transformative treatments that can significantly improve patient outcomes. One of its key product candidates is atacicept, a fusion protein designed for self-administration via a weekly subcutaneous injection. Atacicept works by inhibiting both B lymphocyte stimulator and a proliferation-inducing ligand, which are involved in the production of autoantibodies that contribute to various autoimmune diseases. Additionally, Vera Therapeutics is exploring gene-editing technologies that hold the potential to address conditions such as sickle cell disease and cystic fibrosis.

Blacksmith Medicines is focused on developing innovative therapies that target metal-dependent enzymes, known as metalloenzymes, which play a crucial role in human physiology. With over 30% of known enzymes classified as metalloenzymes, they encompass all major enzyme classes, including oxidoreductases, transferases, and hydrolases. Blacksmith Medicines utilizes a specialized platform that combines a curated library of metal-binding pharmacophores with advanced computational modeling techniques. This approach allows for the rapid and systematic design of small molecule inhibitors that specifically interact with key metal ions within the enzyme's active site. The company's efforts are particularly directed towards creating medicines for immuno-oncology and inflammatory diseases, offering the potential for more effective and selective therapeutic options.

Lexeo Therapeutics is a biotechnology company specializing in adeno-associated virus (AAV)-mediated therapies for both rare and common diseases caused by single gene mutations. Headquartered in New York, the company maintains an integrated pipeline developed in collaboration with Weill Cornell Medicine's Department of Genetic Medicine. Lexeo focuses on advancing its clinical programs towards commercialization while continuing to research new therapies for various patient populations and unmet medical needs.

Myeloid Therapeutics is an immunology company dedicated to harnessing myeloid cells for the treatment of cancer and other diseases. The company employs its ATAK platform technology, which focuses on reprogramming innate immune cells to enhance their ability to target and eliminate cancerous cells. This platform is designed to be versatile and scalable, allowing for the development of various treatment modalities across multiple disease areas. Currently, Myeloid Therapeutics is advancing a cell therapy program aimed at T cell lymphoma, as well as a primed monocyte approach for treating glioblastoma. Through its innovative technology, the company seeks to overcome the limitations of existing cell therapies and improve patient outcomes.

Neurogene Inc., established in 2018 and headquartered in New York, specializes in developing genetic medicines for treating neurological disorders. The company focuses on utilizing adeno-associated virus (AAV) vectors to deliver therapeutic genes for conditions such as Charcot-Marie Tooth disease type 4J (CMT4J), Aspartylglucosaminuria (AGU), and an undisclosed Lysosomal Storage Disease (LSD). Neurogene aims to provide effective treatment options where none currently exist, aiming to improve the quality of life for patients and families affected by these rare neurological disorders.

Faze Medicines is a biotechnology company founded in 2020 and located in Cambridge, Massachusetts. The company focuses on developing small molecule drugs that target the underlying mechanisms of disease pathology, with initial therapeutic efforts directed towards conditions such as amyotrophic lateral sclerosis (ALS) and myotonic dystrophy type 1 (DM1). Faze Medicines employs advanced screening and proteomics techniques to explore biomolecular condensate interaction networks, which aids in the identification and development of novel therapeutics. Through its innovative approach, Faze aims to provide effective treatments for patients suffering from these challenging diseases.

Vigil Neuroscience Inc. is a therapeutics company focused on microglia, the brain's immune sentinel cells, to address both rare and common neurodegenerative diseases. The company aims to restore the vigilance of microglia to improve patient outcomes. Vigil is advancing its lead candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies and is also developing an orally available small molecule TREM2 agonist, VG-3927, which is positioned to enter Investigational New Drug (IND) application. Additionally, Vigil is conducting the IGNITE trial, a Phase 2 proof-of-concept study that represents the first interventional trial for patients with adult-onset leukodystrophy. By leveraging modern neuroscience and various therapeutic modalities, Vigil seeks to deliver precision therapies that enhance the lives of patients and their families while expanding its pipeline and supporting the understanding of microglia biology as a critical therapeutic target.

Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies that target RNA processing to address various diseases. Established in 2018 and based in Cambridge, Massachusetts, the company employs its proprietary biology platform to identify and prioritize therapeutic targets within RNA processing. Through its REMseq platform, Remix Therapeutics validates potential drug targets and optimizes chemical compounds for therapeutic use. The company's approach aims to reprogram RNA processing to control gene expression, thereby correcting, enhancing, or eliminating problematic gene messages. This enables healthcare providers to tackle the underlying causes of diseases, offering novel solutions to previously undruggable conditions.

Dren Bio is a biotechnology company that specializes in protein engineering technologies designed to target and deplete pathogenic cells, protein aggregates, and other disease-causing agents. With a focus on hematologic neoplasms, solid cancers, autoimmune disorders, and diseases related to protein aggregation, the company aims to provide innovative solutions for healthcare professionals in their efforts to combat various serious diseases. Operating under a holding company model, Dren Bio develops multiple projects as standalone assets, seeking to create value through its diverse portfolio of biotechnology initiatives.

Sonoma Biotherapeutics develops adoptive Treg cell therapies aimed at treating autoimmune and degenerative diseases. The company employs advanced genome editing and target-specific cell therapy to create therapeutic solutions that promote self-tolerance and mitigate harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded in 2019 and headquartered in South San Francisco, California, with an additional office in Seattle, Washington, Sonoma Biotherapeutics combines expertise in Treg biology and proprietary methodologies to advance its therapeutic platform, focusing on developing disease-modifying and potentially curative treatments.